INT10170

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.55
First Reported 1984
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 14
Total Number 14
Disease Relevance 3.99
Pain Relevance 3.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Ns5atp9) nucleus (Ns5atp9)
Anatomy Link Frequency
heart 2
blood 1
brain 1
PGE2 1
Ns5atp9 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 51 100.00 Very High Very High Very High
qutenza 7 99.60 Very High Very High Very High
noradrenaline 4 96.84 Very High Very High Very High
Serotonin 3 96.00 Very High Very High Very High
substance P 27 95.72 Very High Very High Very High
Chronic pancreatitis 6 91.76 High High
Neurotransmitter 3 87.92 High High
Clonidine 1 84.04 Quite High
Inflammation 39 79.56 Quite High
Potency 2 78.56 Quite High
Disease Link Frequency Relevance Heat
Bradycardia 3 100.00 Very High Very High Very High
Pressure Volume 2 Under Development 2 99.24 Very High Very High Very High
Toxicity 3 98.20 Very High Very High Very High
Leukopenia 1 93.56 High High
Pancreatitis 11 91.76 High High
Hypersensitivity 5 90.88 High High
Disease 46 88.80 High High
Pressure And Volume Under Development 8 88.72 High High
Neurodegenerative Disease 10 88.36 High High
Necrosis 6 87.40 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These actions of PAF were prevented by pretreatment with the PAF antagonists WEB 2086 (20 mg kg-1) or BN 50739 (10 mg kg-1) 15 min before commencing the infusion.
Negative_regulation (prevented) of PAF associated with antagonist
1) Confidence 0.55 Published 1994 Journal Circ. Shock Section Abstract Doc Link 8149505 Disease Relevance 0.10 Pain Relevance 0.26
These actions of PAF were only partially blocked by drugs blocking receptors for PAF (CV 3988, WEB 2086), thromboxanes (ONO 3708), or leukotrienes (FPL 55712, L-655,240) or by a blocker of eicosanoid production (ibuprofen).
Negative_regulation (blocked) of PAF
2) Confidence 0.43 Published 1991 Journal Circ. Shock Section Abstract Doc Link 1663843 Disease Relevance 0.16 Pain Relevance 0.07
PAF dose-dependently decreased coronary flow, prolonged the P-R interval of the EKG, and decreased heart rate.
Negative_regulation (decreased) of PAF in heart associated with bradycardia
3) Confidence 0.43 Published 1991 Journal Circ. Shock Section Abstract Doc Link 1663843 Disease Relevance 0.16 Pain Relevance 0.07
PAF dose-dependently decreased coronary flow, prolonged the P-R interval of the EKG, and decreased heart rate.
Negative_regulation (decreased) of PAF in heart associated with bradycardia
4) Confidence 0.43 Published 1991 Journal Circ. Shock Section Abstract Doc Link 1663843 Disease Relevance 0.15 Pain Relevance 0.06
BN52021, a PAF antagonist, reduced the accumulation of pancreatic TXB2, 6-keto PGF1 alpha, and PGD2, and did not affect PGE2.
Negative_regulation (antagonist) of PAF in PGE2 associated with antagonist
5) Confidence 0.41 Published 1994 Journal J. Surg. Res. Section Abstract Doc Link 8277767 Disease Relevance 0.73 Pain Relevance 0.42
To investigate the interaction between PAF, TNF-alpha and myocardial depressant factor, the blood levels of these three mediators were evaluated: shocked rats exhibited increased PAF levels with a peak at 30 min.
Negative_regulation (exhibited) of PAF in blood
6) Confidence 0.40 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1468489 Disease Relevance 0.69 Pain Relevance 0.03
In contrast to the inhibition of PAF induced secretion, montelukast did not modulate tachykinin stimulated secretory activity.
Negative_regulation (inhibition) of PAF
7) Confidence 0.38 Published 2008 Journal J Occup Med Toxicol Section Body Doc Link PMC2278150 Disease Relevance 0 Pain Relevance 0.25
The Ca(2+)-contraction in Ca(2+)-free solution was significantly augmented by PAF, whereas the Ca(2+)-contraction in Ca(2+)-free, isotonic high K+ (60 mM) medium was unaffected by PAF. 7.
Neg (unaffected) Negative_regulation (unaffected) of PAF
8) Confidence 0.37 Published 1993 Journal Gen. Pharmacol. Section Abstract Doc Link 8112503 Disease Relevance 0 Pain Relevance 0.15
Inhibition of specific PAF-sensitive receptors await the discovery of specific PAF antagonists.
Negative_regulation (Inhibition) of PAF-sensitive associated with antagonist
9) Confidence 0.35 Published 1984 Journal Prostaglandins Section Abstract Doc Link 6505225 Disease Relevance 0.66 Pain Relevance 0.48
In conclusion, our data show that the clinically used cys-LT1 receptor antagonist montelukast inhibits PAF induced tracheal secretory activity to the same degree as the specific PAF receptor antagonist WEB 2086.
Negative_regulation (inhibits) of PAF associated with antagonist
10) Confidence 0.33 Published 2008 Journal J Occup Med Toxicol Section Body Doc Link PMC2278150 Disease Relevance 0.07 Pain Relevance 0.14
Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.
Negative_regulation (antagonist) of PAF associated with toxicity and antagonist
11) Confidence 0.31 Published 1989 Journal Pharmacol. Res. Section Abstract Doc Link 2594614 Disease Relevance 0.16 Pain Relevance 0.12
However, responses to capsaicin itself and also to PAF were reduced.
Negative_regulation (reduced) of PAF associated with qutenza
12) Confidence 0.28 Published 1990 Journal Am. Rev. Respir. Dis. Section Abstract Doc Link 1967924 Disease Relevance 0.17 Pain Relevance 0.77
BN-52021 could also reduce PAF-induced production of the eicosanoid and thromboxane B in a fetal rat brain [4,71].
Negative_regulation (reduce) of PAF in brain
13) Confidence 0.05 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2820992 Disease Relevance 0.70 Pain Relevance 0.35
The histograms, in Figure 4A, show the increase in fluorescence intensity over the control responses upon the addition of PAF, as well as the inhibitory effect of feG on PAF enhancement of CD11b antibody binding.
Negative_regulation (addition) of PAF
14) Confidence 0.04 Published 2003 Journal BMC Immunol Section Body Doc Link PMC152650 Disease Relevance 0.24 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox